Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report

DelveInsight's "Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Type 2 Diabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Type 2 Diabetes Market Forecast
https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Type 2 Diabetes Market Report:
• The Type 2 Diabetes market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2025, Eli Lilly announced favorable topline results from its Phase III ACHIEVE-1 trial of orforglipron, the company's first oral nonpeptide GLP-1 receptor agonist. The once-daily medication met its primary goal, lowering HbA1c levels by up to 1.6% while demonstrating safety and efficacy comparable to injectable therapies in the same class. At the highest dose, participants also achieved an average weight loss of around 7 kg (7.9%).
• In April 2025, Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company specializing in the development of novel peptide-based therapies, has announced the enrollment of the first participant in its Phase 2b ZUPREME-2 trial. This study targets individuals with overweight or obesity and type 2 diabetes, evaluating the efficacy and safety of once-weekly subcutaneous doses of petrelintide, a long-acting amylin analogue, in comparison to a placebo.
• In February 2025, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system, now approved for use in individuals with type 2 diabetes.
• In February 2025, Sotagliflozin, which has FDA approval for treating type 2 diabetes and kidney disease, has demonstrated a substantial reduction in the risk of heart attack and stroke among high-risk patients, presenting a promising option for cardiovascular protection.
• In January 2025, The FDA has approved a new indication for semaglutide to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as announced by Novo Nordisk.
• As per the Centers for Disease Control and Prevention (CDC), over 34 million individuals in the United States, roughly 1 in 10, are affected by diabetes. The majority, around 90-95%, have type 2 diabetes. While type 2 diabetes commonly arises in individuals aged 45 and older, there is a growing trend of its occurrence among children, teenagers, and young adults.
• As per the Centers for Disease Control and Prevention, over 34 million people in the United States-roughly 1 in 10-are living with diabetes, with around 90-95% of these cases being type 2 diabetes. While it typically occurs in adults over the age of 45, an increasing number of children, teenagers, and young adults are also being diagnosed with the condition.
• According to Diabetes UK, type 2 diabetes is the most common form of the disease, making up approximately 90% of all diabetes cases in the United Kingdom.
• Over 34 million individuals in the United States-around 1 in 10-are living with diabetes, with type 2 diabetes accounting for roughly 90-95% of these cases. While it typically emerges in adults over the age of 45, an increasing number of children, teenagers, and young adults are also being diagnosed (Centers for Disease Control and Prevention, n.d.).
• Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
• Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
• The Type 2 Diabetes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Type 2 Diabetes pipeline products will significantly revolutionize the Type 2 Diabetes market dynamics.

Type 2 Diabetes Overview
Type 2 diabetes is a chronic metabolic disorder characterized by elevated levels of blood glucose (sugar). It is the most common form of diabetes and typically develops in adulthood, though it can occur in children as well. In type 2 diabetes, the body either resists the effects of insulin (a hormone that helps regulate blood sugar) or doesn't produce enough insulin to maintain normal blood glucose levels.

Get a Free sample for the Type 2 Diabetes Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/type-2-diabetes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Type 2 Diabetes Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Type 2 Diabetes Epidemiology Segmentation:
The Type 2 Diabetes market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Type 2 Diabetes
• Prevalent Cases of Type 2 Diabetes by severity
• Gender-specific Prevalence of Type 2 Diabetes
• Diagnosed Cases of Episodic and Chronic Type 2 Diabetes

Download the report to understand which factors are driving Type 2 Diabetes epidemiology trends @ Type 2 Diabetes Epidemiology Forecast
https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Type 2 Diabetes Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Type 2 Diabetes market or expected to get launched during the study period. The analysis covers Type 2 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Type 2 Diabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Type 2 Diabetes Therapies and Key Companies
• Tirzepatide/LY3298176: Eli Lilly and Company
• Danuglipron: Pfizer
• RGT001-075: Regor Pharmaceuticals Inc.
• AZD0186: AstraZeneca
• ECC5004: Eccogene
• PF-07081532: Pfizer
• XW014: Sciwind Biosciences USA Co., Ltd.
• MN-001: MediciNova
• SPI-62: Sparrow Pharmaceuticals
• HTD1801: HighTide Biopharma Pty Ltd
• Semaglutide: Novo Nordisk A/S
• BMF-219: Biomea Fusion Inc.
• ALT-801: Altimmune, Inc.
• MBL949: Novartis
• LY3457263: Eli Lilly and Company
• AMG 133: Amgen
• DD01: Neuraly, Inc.
• CT-868: Carmot Therapeutics, Inc.
• IVA337: Inventiva Pharma
• INV-202: Inversago Pharma Inc
• AT-001: Applied Therapeutics, Inc.

Discover more about therapies set to grab major Type 2 Diabetes market share @ Type 2 Diabetes Treatment Landscape
https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Type 2 Diabetes Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
• Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
• Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
• Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Type 2 Diabetes Unmet Needs, KOL's views, Analyst's views, Type 2 Diabetes Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.